Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein SL-172154 (SIRPα-Fc-CD40L) in patients with higher-risk myelodysplastic syndrome or acute myeloid leukemia.
Combining a new immune-targeting drug with standard leukemia treatment shows promise in early testing, though survival gains need further investigation.
This clinical trial sought to determine whether SL-172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher-risk myelodysplastic syndrome (HR-MDS) or acute myeloid leukemia (AML). SL-172154 plus AZA was generally well tolerated with favorable CR rates in pts with TP53m HR-MDS or AML, although without substantial improvement in OS when compared to historical benchmarks for AZA or AZA/VEN, respectively.
What the study was
- Study design
- Phase 1 clinical trial
- Population
- Patients with AML or higher-risk MDS
- Sample size
- 33
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer
Why it surfaced
Matched Hematologic malignancies; Phase 1 clinical trial; human evidence; conservative score 9/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.